Tyr1604

Site Information
tAPGAGHyEDTILkS SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 447828
Available spectra: 3 CST
Associated spectra: 3 CST

In vivo Characterization
Methods used to characterize site in vivo:	2D analysis ( 66 ) , flow cytometry ( 16 ) , immunoassay ( 1 , 5 ) , immunoprecipitation ( 6 , 24 ) , mass spectrometry ( 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 ) , mutation of modification site ( 4 , 65 , 66 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 16 , 24 , 66 ) , phosphopeptide mapping ( 66 ) , western blotting ( 1 , 2 , 3 , 4 , 6 , 66 )
Disease tissue studied:	adrenal cancer ( 24 ) , brain cancer ( 24 ) , glioblastoma ( 24 ) , glioma ( 24 ) , gastric cancer ( 22 , 23 ) , gastric carcinoma ( 22 , 23 ) , lung cancer ( 5 , 6 , 11 , 12 , 13 , 14 , 15 , 31 , 38 , 43 ) , non-small cell lung cancer ( 5 , 6 , 9 , 11 , 12 , 13 , 14 , 15 , 31 , 38 , 43 ) , non-small cell lung adenocarcinoma ( 5 , 6 , 9 , 11 , 12 , 13 , 14 , 15 , 31 ) , lymphoma ( 2 , 16 , 35 , 39 , 40 , 45 , 48 , 49 , 52 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 66 ) , anaplastic large cell lymphoma ( 2 , 16 , 35 , 39 , 40 , 45 , 48 , 49 , 52 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 66 ) , non-Hodgkin's lymphoma ( 66 ) , T cell lymphoma ( 16 ) , Merkel cell carcinoma ( 5 ) , neuroblastoma ( 4 , 6 , 8 , 17 , 18 , 19 , 20 , 25 , 28 , 29 , 30 , 33 , 34 ) , melanoma skin cancer ( 32 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 24 ) , 293GP (epithelial) [NPM-ALK (human), transfection] ( 21 ) , 3T3 (fibroblast) ( 1 , 4 ) , BaF3 ('B lymphocyte, precursor') ( 65 , 66 ) , CHP212 (neural crest) ( 4 ) , COST ( 2 ) , DL-40 ( 2 ) , HEK293T (epithelial) ( 37 , 41 , 42 , 44 , 46 , 47 , 50 , 51 , 53 , 54 ) , JB-6 (lymphocyte) ( 2 , 56 ) , Karpas-299 (T lymphocyte) ( 16 , 45 , 52 , 59 , 60 , 66 ) , LAN-6 (neural crest) ( 8 , 25 ) , lymphocyte ( 2 ) , Mac-2A ( 2 ) , MCC (fibroblast) ( 5 ) , MCC13 ( 5 ) , MCC14/2 ( 5 ) , MCC26 ( 5 ) , MKL1 ( 5 ) , MKL2 ( 5 ) , MKN-45 (gastric) ( 22 , 23 ) , mononuclear-blood ( 2 ) , MS1 (endothelial) ( 5 ) , NB1 ( 3 , 4 ) , NCI-H2228 (pulmonary) ( 5 , 9 , 27 , 38 , 43 ) , NCI-H3122 (pulmonary) ( 6 , 11 , 12 , 13 , 14 , 15 , 31 ) , NGP ( 4 ) , OCI-Ly13.2 ( 2 ) , PETA ( 5 ) , Rat1 (fibroblast) ( 66 ) , SH-SY5Y (neural crest) ( 6 , 8 , 17 ) , SK-N-BE(2) (neural crest) ( 8 , 18 , 19 , 20 ) , skin ( 5 , 32 ) , SKNAS (neural crest) ( 4 ) , SMS-KCN (neural crest) ( 8 , 28 , 29 , 30 , 33 , 34 ) , SMS-KCN-A (neural crest) ( 8 ) , SR (T lymphocyte) ( 48 ) , SU-DHL1 (T lymphocyte) ( 2 , 52 , 57 , 58 , 61 , 62 , 63 , 64 ) , SUP-M2 (T lymphocyte) ( 16 , 49 ) , SW13 (adrenal) ( 24 ) , TS (lymphocyte) ( 2 , 35 , 39 , 40 , 55 ) , U-138 MG (glial) ( 24 ) , U87MG (glial) ( 24 ) , WAGA ( 5 )

Upstream Regulation
Regulatory protein:	ODZ3 (human) ( 1 )
Putative in vivo kinases:	ALK (human) ( 3 )
Putative upstream phosphatases:	PTP1B (human) ( 2 ) , PTPN2 (human) ( 2 )
Treatments:	ceritinib ( 6 ) , crizotinib ( 1 , 2 , 6 , 16 ) , dermatan sulphate ( 3 ) , heparin sodium ( 3 ) , lorlatinib ( 1 ) , LY294002 ( 6 ) , NVP-TAE684 ( 6 ) , scFv-107 ( 24 ) , U0126 ( 6 )

Downstream Regulation
Effects of modification on ALK:	enzymatic activity, induced ( 1 , 3 ) , intracellular localization ( 1 ) , molecular association, regulation ( 66 ) , phosphorylation ( 1 )
Effects of modification on biological processes:	carcinogenesis, induced ( 1 ) , cell cycle regulation ( 66 ) , cell growth, induced ( 1 )
Induce interaction with:	PLCG1 (mouse) ( 66 )

Disease / Diagnostics Relevance
Relevant diseases:	Merkel cell carcinoma ( 5 )

References
1	Hiwatari M, et al. (2022) Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma. Oncogene 41 35411036 Curated Info
2	Karaca Atabay E, et al. (2022) Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood 139, 717-731 34657149 Curated Info
3	Machino M, et al. (2021) Dermatan sulfate is an activating ligand of anaplastic lymphoma kinase. J Biochem 170 34270745 Curated Info
4	Huang H, et al. (2021) Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration. Cell Rep 36, 109363 34260934 Curated Info
5	Jaatinen J, et al. (2021) ALK is frequently phosphorylated in Merkel cell carcinoma and associates with longer survival. PLoS One 16, e0252099 34029351 Curated Info
6	Emdal KB, et al. (2018) Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma. Sci Signal 11 30459283 Curated Info
7	Wang R, et al. (2017) Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells. Cancer Sci 108, 1203-1209 28370702 Curated Info
8	Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130 25884760 Curated Info
9	Rikova K (2013) CST Curation Set: 18449; Year: 2012; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954 Curated Info
10	Rikova K (2012) CST Curation Set: 14271; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
11	Rikova K (2012) CST Curation Set: 13327; Year: 2012; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
12	Possemato A (2011) CST Curation Set: 11907; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
13	Possemato A (2011) CST Curation Set: 11908; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
14	Possemato A (2011) CST Curation Set: 11919; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
15	Possemato A (2011) CST Curation Set: 11920; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
16	Drew AE, et al. (2011) Comparison of 2 cell-based phosphoprotein assays to support screening and development of an ALK inhibitor. J Biomol Screen 16, 164-73 21297104 Curated Info
17	Guo A (2010) CST Curation Set: 10556; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
18	Guo A (2010) CST Curation Set: 10551; Year: 2010; Biosample/Treatment: cell line, SKNBE(2)/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
19	Guo A (2010) CST Curation Set: 10549; Year: 2010; Biosample/Treatment: cell line, SKNBE(2)/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
20	Guo A (2010) CST Curation Set: 10548; Year: 2010; Biosample/Treatment: cell line, SKNBE(2)/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
21	Wu F, et al. (2010) Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Mol Cell Proteomics 9, 1616-32 20393185 Curated Info
22	Moritz A (2010) CST Curation Set: 9979; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
23	Moritz A (2010) CST Curation Set: 9775; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
24	Stylianou DC, et al. (2009) Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene 28, 3296-306 19633684 Curated Info
25	Guo A (2009) CST Curation Set: 6125; Year: 2009; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
26	Rikova K (2008) CST Curation Set: 5693; Year: 2008; Biosample/Treatment: cell line, H3122 Silac inh1/inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
27	Rikova K (2008) CST Curation Set: 5328; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
28	Guo A (2008) CST Curation Set: 5180; Year: 2008; Biosample/Treatment: cell line, SMS-KCN/BDNF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
29	Guo A (2008) CST Curation Set: 5181; Year: 2008; Biosample/Treatment: cell line, SMS-KCN/BDNF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
30	Guo A (2008) CST Curation Set: 5182; Year: 2008; Biosample/Treatment: cell line, SMS-KCN/BDNF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
31	Rikova K (2008) CST Curation Set: 4947; Year: 2008; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
32	Tucker M (2008) CST Curation Set: 4870; Year: 2008; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
33	Stokes M (2007) CST Curation Set: 3492; Year: 2007; Biosample/Treatment: cell line, SMS-KCN/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
34	Stokes M (2007) CST Curation Set: 3494; Year: 2007; Biosample/Treatment: cell line, SMS-KCN/NGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
35	Goss V (2006) CST Curation Set: 1306; Year: 2006; Biosample/Treatment: cell line, TS/A1; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
36	Goss V (2006) CST Curation Set: 1307; Year: 2006; Biosample1/Treatment/Isotope: cell line, 293T/none/L, Biosample2/Treatment/Isotope: cell line, 293T/none/H; Disease: -; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
37	Goss V (2006) CST Curation Set: 1308; Year: 2006; Biosample1/Treatment/Isotope: cell line, 293T/none/L, Biosample2/Treatment/Isotope: cell line, 293T/none/H; Disease: -; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
38	Possemato A (2006) CST Curation Set: 1115; Year: 2006; Biosample/Treatment: cell line, NCI-H2228/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
39	Goss V (2005) CST Curation Set: 976; Year: 2005; Biosample/Treatment: cell line, TS/B2; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
40	Goss V (2005) CST Curation Set: 970; Year: 2005; Biosample/Treatment: cell line, TS/A1; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
41	Boccalatte F (2005) CST Curation Set: 756; Year: 2005; Biosample1/Treatment/Isotope: cell line, 293T/Tetracyclin/L, Biosample2/Treatment/Isotope: cell line, 293T/Tetracyclin/H; Disease: -; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
42	Boccalatte F (2005) CST Curation Set: 757; Year: 2005; Biosample1/Treatment/Isotope: cell line, 293T/Tetracyclin/L, Biosample2/Treatment/Isotope: cell line, 293T/Tetracyclin/H; Disease: -; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
43	Rikova K (2005) CST Curation Set: 733; Year: 2005; Biosample/Treatment: cell line, NCI-H2228/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
44	Boccalatte F (2005) CST Curation Set: 677; Year: 2005; Biosample1/Treatment/Isotope: cell line, 293T/Tetracyclin/L, Biosample2/Treatment/Isotope: cell line, 293T/Tetracyclin/H; Disease: -; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
45	Boccalatte F (2005) CST Curation Set: 614; Year: 2005; Biosample/Treatment: cell line, Karpas-299/-; Disease: T cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
46	Boccalatte F (2005) CST Curation Set: 599; Year: 2005; Biosample1/Treatment/Isotope: cell line, 293T/Tetracyclin/L, Biosample2/Treatment/Isotope: cell line, 293T/Tetracyclin/H; Disease: -; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
47	Boccalatte F (2005) CST Curation Set: 600; Year: 2005; Biosample1/Treatment/Isotope: cell line, 293T/Tetracyclin/L, Biosample2/Treatment/Isotope: cell line, 293T/Tetracyclin/H; Disease: -; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
48	Boccalatte F (2005) CST Curation Set: 537; Year: 2005; Biosample/Treatment: cell line, SR-786/-; Disease: T cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
49	Boccalatte F (2005) CST Curation Set: 538; Year: 2005; Biosample/Treatment: cell line, SUP-M2/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
50	Boccalatte F (2005) CST Curation Set: 539; Year: 2005; Biosample/Treatment: cell line, 293T/Tetracyclin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
51	Boccalatte F (2005) CST Curation Set: 540; Year: 2005; Biosample/Treatment: cell line, 293T/Tetracyclin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
52	Rush J, et al. (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23, 94-101 15592455 Curated Info
53	Boccalatte F (2004) CST Curation Set: 507; Year: 2004; Biosample/Treatment: cell line, 293T/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
54	Boccalatte F (2004) CST Curation Set: 508; Year: 2004; Biosample/Treatment: cell line, 293T/serum starved &'\|\|' Tetracyclin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
55	Boccalatte F (2004) CST Curation Set: 484; Year: 2004; Biosample/Treatment: cell line, TS/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
56	Boccalatte F (2004) CST Curation Set: 483; Year: 2004; Biosample/Treatment: cell line, JB-6/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
57	Moritz A (2004) CST Curation Set: 398; Year: 2004; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
58	Moritz A (2003) CST Curation Set: 224; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
59	Moritz A (2003) CST Curation Set: 178; Year: 2003; Biosample/Treatment: cell line, Karpas-299/-; Disease: T cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
60	Moritz A (2003) CST Curation Set: 179; Year: 2003; Biosample/Treatment: cell line, Karpas-299/-; Disease: T cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
61	Moritz A (2003) CST Curation Set: 182; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
62	Moritz A (2003) CST Curation Set: 165; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
63	Moritz A (2003) CST Curation Set: 168; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
64	Moritz A (2003) CST Curation Set: 170; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
65	Bai RY, et al. (2000) Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96, 4319-27 11110708 Curated Info
66	Bai RY, et al. (1998) Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 18, 6951-61 9819383 Curated Info